Literature DB >> 10318864

CTLA-4 ligation suppresses CD28-induced NF-kappaB and AP-1 activity in mouse T cell blasts.

C Olsson1, K Riesbeck, M Dohlsten, E Michaëlsson, K Riebeck.   

Abstract

The effects of cytotoxic lymphocyte antigen 4 (CTLA-4) on CD3/CD28 monoclonal antibody (mAb) activation of CD4(+)/CTLA-4(+) blastoid T cells were studied in an in vitro model system. As previously reported, coligation of CTLA-4 mAb results in suppression of T cell proliferation and cytokine production. The proliferation but not the interleukin 2 (IL-2) production could be restored by addition of exogenous IL-2, suggesting that the inhibitory effect occurred at the level of IL-2 production rather than at the regulation of the IL-2 receptor pathway. To study the effects on nuclear factors critical for T cell activation, we analyzed the levels of the transcription factors NF-kappaB and AP-1. These were potently induced in CD3/CD28 mAb-restimulated T cells. In contrast, CTLA-4 ligation strongly suppressed the induction of both transcription factors. The compositions of NF-kappaB and AP-1 family members were similar, irrespective of stimulation conditions. Analyses of the NF-kappaB regulator IkappaB-alpha revealed similar levels of IkappaB-alpha protein in the preparations. However, a reduced phosphorylation of IkappaB-alpha in CTLA-4 coengaged T cell blasts compared with T cells ligated with CD3/CD28 was found. Previous studies have concluded that CTLA-4 ligation regulates T cell activation by inhibiting the T cell receptor-mediated signals. However, the present findings propose that the major impact of CTLA-4 ligation is inhibition of signals mediated by CD28.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10318864     DOI: 10.1074/jbc.274.20.14400

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

Review 2.  CTLA-4 and tolerance: the biochemical point of view.

Authors:  Shunsuke Chikuma; Jeffrey A Bluestone
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 3.  At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Authors:  Andrew M Intlekofer; Craig B Thompson
Journal:  J Leukoc Biol       Date:  2013-04-26       Impact factor: 4.962

4.  Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells.

Authors:  F Luhder; C Chambers; J P Allison; C Benoist; D Mathis
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

5.  CTLA-4 polymorphisms: influence on transplant-related mortality and survival in children undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Judith Hammrich; Susan Wittig; Thomas Ernst; Bernd Gruhn
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-15       Impact factor: 4.553

6.  CTLA-4 interacts with STAT5 and inhibits STAT5-mediated transcription.

Authors:  M Srahna; L A Van Grunsven; J E Remacle; P Vandenberghe
Journal:  Immunology       Date:  2006-03       Impact factor: 7.397

7.  Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation.

Authors:  Karin Knieke; Holger Lingel; Kathrin Chamaon; Monika C Brunner-Weinzierl
Journal:  PLoS One       Date:  2012-03-06       Impact factor: 3.240

Review 8.  Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment.

Authors:  Giulia Di Dalmazi; Silvia Ippolito; Isabella Lupi; Patrizio Caturegli
Journal:  Expert Rev Endocrinol Metab       Date:  2019-11

Review 9.  CD28 and CTLA-4 coreceptor expression and signal transduction.

Authors:  Christopher E Rudd; Alison Taylor; Helga Schneider
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 10.  CTLA-4 trafficking and surface expression.

Authors:  Elke Valk; Christopher E Rudd; Helga Schneider
Journal:  Trends Immunol       Date:  2008-05-09       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.